Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using microRNA-21
Patent Number: 8,084,199
Filed: July 12, 2007
Lead Inventor: Carlo Croce, Ohio State University
The invention provides “novel methods and compositions for the diagnosis and treatment of colon cancers,” the patent's abstract states. “The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Bioinformatically Detectable Group of Novel Regulatory Oligonucleotides and Uses Thereof
Patent Number: 8,084,598
Filed: Jan. 29, 2004
Inventor: Isaac Bentwich, Rosetta Genomics
“The invention relates to a first group of novel oligonucleotides, here identified as genomic address messenger, or GAM, oligonucleotides, and a second group of novel operon-like polynucleotides, here identified as genomic record, or GR, polynucleotides,” the patent's abstract states. “GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided ... encoding 2147 GAM oligonucleotides and 313 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules.” Also claimed are “methods and systems for detecting GAM oligonucleotides and GR polynucleotide, and specific functions and utilities thereof for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”
Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA
Patent Number: 8,084,599
Filed: March 15, 2005
Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)
“The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene,” the patent's abstract states. “More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.”
Title: Short Interfering Ribonucleic Acid with Improved Pharmacological Properties
Patent Number: 8,084,600
Filed: May 2, 2007
Lead Inventor: Francois Jean-Charles Natt, Novartis
The invention, the patent's abstract states, comprises “short interfering ribonucleic acid for oral administration [with] siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.”
Title: Cross-Linking Agent, Cross-Linking Method, Method for Controlling Gene Expression, and Method of Examining Gene Function
Patent Number: 8,084,625
Filed: Feb. 27, 2006
Lead Inventor: Toshiaki Furuta, Wako Pure Chemical Industries
The invention, the patent's abstract states, “provides a cross-linking agent [that has] photodegradable protective groups at two ends to cross-link double-stranded nucleic acid; a nucleic acid and a protein or a polypeptide; or proteins or polypeptides.”
The invention also comprises “a method for cross-linking a double-stranded RNA or the like using the same; a method for regulating gene expression, which can control the expression of a target gene at an arbitrary timing and location; and a method for examining a gene function,” the abstract states. “Cross-linking between double-stranded nucleic acids between a nucleic acid and a protein or a polypeptide, or between proteins or polypeptides … can be easily formed. … In addition, the cross-linking can also be easily removed so that the expression of a target gene can be easily controlled at an arbitrary timing and location with high efficiency. Hence, as a result, function examination and/or identification of a gene that is expressed at a specific timing and location can be performed. In addition, the RNAi effect of a double-stranded RNA that cannot be easily inhibited by a conventional caged compound can be inhibited, and the expression of a target gene can be easily controlled at an arbitrary timing and location.”
Title: DNA Virus microRNA and Methods for Inhibiting Same
Patent Number: 8,088,902
Filed: Oct. 19, 2004
Lead Inventor: Sebastien Pfeffer, Rockefeller University
“The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA,” the patent's abstract states. “In another embodiment, the invention relates to single-stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.”
Title: Compositions and Methods for Therapy and Diagnosis of Cancer
Patent Number: 8,088,913
Filed: Dec. 7, 2006
Lead Inventor: Ugur Sahin, Ganymed Pharmaceuticals
The invention, the patent's abstract states, is “directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The ... invention also includes methods which make [it] possible to assess and/or prognose the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer.”
Title: microRNA and Methods for Inhibiting Same
Patent Number: 8,088,914
Filed: July 6, 2009
Lead Inventor: Markus Stoffel, Rockefeller University
“The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA,” according to the patent's abstract. “In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.”
Title: Functional and Hyperfunctional siRNA
Patent Number: 8,090,542
Filed: Nov. 14, 2003
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes.”
Titles: Novel Lipids and Compositions for the Delivery of Therapeutics
Application Numbers: 20110311583; 20110311582
Filed: Nov. 10, 2009
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
The inventions, the patent applications' abstracts state, relate to “lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.”
Title: RNAi-Based Selection System
Application Number: 20110311985
Filed: Feb. 9, 2010
Inventor: Peter Hahn, Qiagen
The invention provides a “novel RNAi-based selection system for selecting host cells that have incorporated an expression vector,” the patent application's abstract states.
Title: Diagnostic and Prognostic Use of Human Bladder Cancer-Associated microRNAs
Application Number: 20110312516
Filed: March 18, 2011
Lead Inventor: Torben Orntoft, Catalyst Assets
The invention “is based, at least in part, upon discovery of a number of miRNAs having expression that significantly correlates with bladder cancer, including certain stages or types of bladder cancer, as well as with bladder cancer survival and/or responsiveness to bladder cancer therapies,” the patent application's abstract states. “Accordingly, the ... invention features the identification and use of miRNAs to detect, diagnose, and/or predict the course, progression, or therapy responsiveness of bladder cancer. Kits for performing such assessments, and for administering therapeutic agents to subjects diagnosed with bladder cancer or certain forms of bladder cancer using the methods of the invention, are also featured.”
Title: Engineered Tunable Nanoparticles for Delivery of Therapeutics, Diagnostics, and Experimental Compounds and Related Compositions for Therapeutic Use
Application Number: 20110312877
Filed: Feb. 26, 2009
Lead Inventor: Mark Berninger, Aparna Biosciences
The invention comprises “biomedical nanoparticles ... based on new engineered modular carrier macromolecules, on engineered macromolecules or associated entities providing an internal nanoparticle structure, and compositions for minimizing non-specific binding of the nanoparticles while enabling efficient and convenient targeting to cells and tissues,” according to the patent application's abstract. “These nanoparticles may be used to deliver atomic or molecular or associated entities which are useful for diagnostics, primarily in vivo imaging, for therapeutics, for vaccines, or for experimental research. Nanoparticles comprising combinations of active entities such as gene inhibitors with gene expression cassettes or imaging agents with therapeutic agents, and polyamide compounds useful for treatment of microbial infections are also disclosed.”
Title: HDL Particles for Delivery of Nucleic Acids
Application Number: 20110312899
Filed: Nov. 17, 2009
Lead Inventor: Anil Sood, UNT Health Sciences Center
The invention comprises “high-density lipoprotein-nucleic acid particles, wherein the particles include an apolipoprotein; a nucleic acid component comprising a therapeutic nucleic acid segment; and a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component,” the patent application's abstract states. “Also disclosed are pharmaceutical compositions that include an apolipoprotein; a nucleic acid component comprising a therapeutic nucleic acid segment; and a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.”
Title: SNALP Formulations Containing Polyoxazoline-Dialkyloxypropyl Conjugates
Application Number: 20110313017
Filed: Jan. 13, 2011
Inventor: James Heyes, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
The invention, the patent application's abstract states, claims “polyoxaline-dialkyloxypropyl conjugates, SNALP compositions comprising POZ-DAA conjugates, and methods of using such SNALP compositions to introduce a therapeutic agent, such as a nucleic acid, into a cell.”
Title: Treatment of Intestinal Conditions
Application Number: 20110313016
Filed: March 14, 2006
Lead Inventor: Ana Jimenez, Sylentis
The invention comprises “methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease,” according to the patent application's abstract. “Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.”
Title: UsiRNA Compositions
Application Number: 20110313020
Filed: Dec. 3, 2009
Lead Inventor: Michael Templin, Marina Biotech
The invention comprises “double-stranded RNA complexes having one or more hydroxymethyl substituted nucleomonomers in the passenger strand of an RNA complex,” the patent application's abstract states. “RNA complexes of the disclosure may be useful for therapeutic applications, diagnostic applications, or research applications.”
Title: RNAi Modulation of RSV and Therapeutic Uses Thereof
Application Number: 20110313023
Filed: June 14, 2011
Inventor: Rachel Meyers, Alnylam Pharmaceuticals
The invention is “based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents, as well as by parenteral administration of such agents,” the patent application's abstract states. “Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels, and viral titers in a subject.”
Title: RNA Interference-Mediated Inhibition of Proprotein Convertase Subtilisin Kexin 9 Gene Expression Using Short Interfering Nucleic Acid
Application Number: 20110313024
Filed: July 25, 2011
Lead Inventor: Leonid Beigelman, Merck
The invention “relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of proprotein convertase subtilisin kexin 9 gene expression and/or activity,” the patent application's abstract states. “Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules... capable of mediating RNA interference against PCSK9 gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules.”
Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules
Application Number: 20110313025
Filed: July 25, 2011
Lead Inventor: David Brown, Asuragen
The invention comprises “methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules,” the patent application's abstract states. “Moreover, the ... invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.”
Title: iRNA Agents Targeting CCR5-Expressing Cells and Uses Thereof
Application Number: 20110313144
Filed: Aug. 23, 2011
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
“The invention relates to iRNA agents that preferably include a modification that targets CC chemokine receptor 5,” the patent application's abstract states. “The invention also relates to methods of making and using such modified iRNA agents.”
Title: Method to Trigger RNA Interference
Application Number: 20110314571
Filed: Aug. 24, 2011
Lead Inventor: James Carrington, Oregon State University
The invention, the patent application's abstract states, comprises a “method to generate siRNAs in vivo, [as well as] constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.”
Title: Cell Type-Specific Aptamer-siRNA Delivery System for HIV-1 Therapy
Application Number: 20110318838
Filed: Sept. 12, 2011
Lead Inventor: John Rossi, City of Hope
The invention “relates to compositions and methods for delivery of siRNA to specific cells or tissue,” according to the patent application's abstract. “More particularly, the present invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer.”
Title: siRNA Targeting Histamine Receptor H1
Application Number: 20110319296
Filed: Aug. 10, 2011
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”
Title: siRNA Targeting Gremlin
Application Number: 20110319297
Filed: Aug. 23, 2011
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1.”
Title: Cell Specifically Effective Molecules on the Basis of siRNA and Application Kits for the Production Thereof and Use Thereof
Application Number: 20110319342
Filed: March 12, 2010
Lead Inventor: Tobias Poehlmann, BianoScience
The invention comprises “a biologically inactivated [cell-specific] effective molecule for biologically inactive transfection into a target cell to inhibit expression of genes in the target cell after biological activation of the molecule,” according to the patent application's abstract.
Title: siRNA Targeting Cyclin-Dependent Kinase 4
Application Number: 20110319474
Filed: Aug. 17, 2011
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”